System comparison
Emcyte PurePRP vs Arthrex Angel
The Angel system is an automated, sensor-driven machine that lets you dial in concentration, hematocrit, and delivery volume across a wide range of starting blood volumes. Emcyte PurePRP SP is a disposable-kit system with a fixed validated protocol per kit. The real choice is between programmable range and procedural simplicity, and between two very different capital positions.
Disclosure: PRP Direct is an Emcyte distributor. We have a commercial interest in one of the systems on this page. Every Arthrex figure below is quoted from Arthrex's own published material with a link and a date. Read the section on how to compare the concentration numbers before you compare them, because the two companies publish different kinds of figure and stacking them side by side would mislead you.
The 18x versus 6x trap
Arthrex states the Angel system has the capability to deliver platelet concentrations up to 18x baseline with adjustable leukocyte concentrations. Emcyte states PurePRP SP delivers at least 6x. Those look like they belong in the same column. They do not.
One is a ceiling: the top of a programmable range, achieved at a particular setting and a particular starting volume. The other is a floor: what the manufacturer says the kit delivers as a minimum on its standard protocol. A ceiling and a floor cannot be subtracted from each other, and any comparison that presents "18x versus 6x" as a gap is doing something dishonest with two honest numbers.
If you are evaluating both, ask each manufacturer the same question in the same form: at my typical draw volume and my typical settings, what concentration and what output volume should I expect, and what is the variability. That question is answerable and comparable. "What is your headline multiple" is neither.
The published specifications
Angel figures are as published by Arthrex. Emcyte figures are manufacturer-reported. Rows are matched only where the two companies publish the same kind of figure.
| Specification | Emcyte PurePRP SP | Arthrex Angel |
|---|---|---|
| System type | Disposable kit, fixed validated protocol per kit | Automated device, sensor-driven, one-button operation |
| Concentration figure published | ≥ 6x baseline (a stated minimum) | Up to 18x baseline (a stated capability ceiling) |
| Starting blood volume | 30 / 60 / 120 mL kits | 40 mL to 180 mL, variable volume separation chamber |
| Output volume | 7 mL from the 60 mL kit | Customizable delivery volume |
| Leukocyte control | Selectable, neutrophil-rich or neutrophil-poor | Adjustable leukocyte concentrations |
| Hematocrit control | < 1% in the final PRP, per the kit protocol | Hematocrit settings customizable by the operator |
| Separation principle | Density separation across two spins | Flow cytometry principle, light absorption by cells, 3-sensor technology |
| Capital equipment | Sapphire Series centrifuge, also runs bone marrow and adipose kits | Dedicated Angel system centrifuge |
| Bone marrow processing | Separate PureBMC kit family on the same centrifuge | Processes bone marrow aspirate on the same system |
| Regulatory status | Both are 510(k)-cleared blood-processing devices. Clearance covers processing, not treatment of any condition. | |
Angel specifications from the Arthrex Angel System product page (arthrex.com, retrieved 2026-07-25) and the Angel Concentrated Platelet Rich Plasma System Operator's Manual (Arthrex DFU-0262-3). Emcyte specifications are manufacturer-reported from the PurePRP SP product documentation and instructions for use. Figures describe device output and operating range, not clinical performance.
About the head-to-head study you will be shown
There is a 2015 paired-donor lab comparison, run by BioSciences Research Associates in Cambridge, that reports higher cell concentration and growth-factor means for Emcyte over both the Arthrex Angel and Harvest Clear PRP. A distributor will probably show it to you, including us if you ask.
Here is what you should know before you weigh it. It was commissioned by Emcyte, so it is a vendor-sponsored study rather than independent research. It used seven donors, which is a small sample. It is from 2015, so it predates a decade of revisions on both sides. And it tested PurePRP II, an earlier generation, not the PurePRP SP kit sold today.
That does not make it worthless, and its process-time findings are useful context. It does mean it should not be the reason you choose a system, and we are not going to present it as though it settles the question. If a supplier hands you a comparison study without telling you who paid for it, ask.
The decision is mostly about capital and range
Angel buys you a programmable envelope. If you genuinely need to vary concentration, hematocrit, and delivery volume case by case, or if you routinely process starting volumes well above 60 mL, that range is the argument, and no kit-based system replicates it.
The kit approach buys you a lower capital entry, a fixed protocol that is harder to run inconsistently, and a centrifuge that also runs bone marrow and adipose kits. If your protocol is stable and you would set the machine the same way every time, programmability is capability you are paying for and not using.
Common questions
Does the Arthrex Angel really produce 18x PRP?
Arthrex publishes 18x as a capability ceiling, the top of a programmable range at particular settings, not a figure every run produces. Ask what concentration and output volume to expect at your typical draw volume and settings, which is the comparable question across any two systems.
Is Emcyte or Arthrex Angel better?
Neither is better in the abstract and we will not claim otherwise. Angel offers a programmable range across a wide starting volume; a kit system offers lower capital entry and a fixed protocol that is harder to run inconsistently. Match the choice to whether your protocol actually varies.
Can both systems process bone marrow?
Yes, by different routes. Arthrex publishes bone marrow aspirate processing on the Angel system itself. Emcyte uses a separate PureBMC kit family that runs on the same Sapphire centrifuge, so a practice adds a disposable rather than another machine.
Is the Emcyte comparison study independent?
No. The 2015 BioSciences Research Associates comparison was commissioned by Emcyte, used seven donors, and tested PurePRP II rather than the current PurePRP SP kit. Treat it as vendor-sponsored context, not as independent evidence, and weigh it accordingly.
Comparing systems for a real caseload?
Tell us your draw volumes and whether your protocol varies case to case. We'll send itemized pricing and say plainly where a kit system is the wrong answer. One business day, no login wall.
Request a quotePRP Direct is an Emcyte distributor. Competitor specifications are quoted from the manufacturers' own published materials and are their statements, not ours. All systems referenced are 510(k)-cleared blood-processing devices; clearance covers how a device processes blood and is not a clearance of the prepared PRP to treat any condition, and no PRP therapy is FDA-approved for a specific indication. Manufacturer specifications are not claims of clinical efficacy. This page is general education and is not medical advice. Product names and trademarks belong to their respective owners.